Clinical trials: gemcitabine hydrochloride
Sarcoma, Soft Tissue Sarcoma
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Metastatic Sarcoma, Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT04906876
- Testing
- Gemcitabine, Docetaxel, 9-ING-41
- Where
- 2 sites in United States
- Sponsor
- Brown University
Advanced Cancer
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of Abraxane (nab-paclitaxel), Gemzar (gemcitabine), and Avastin (bevacizumab) that can be given to patients with advanced cancer.
- Trial name
- NCT01113476
- Testing
- Nab-paclitaxel, Bevacizumab, Gemcitabine
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer, Ductal Adrenocarcinoma
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
The purpose of this study is to evaluate the safety and tolerability of selected dose 1.2mg/kg BID dosage administered subcutaneously (SC) administered PCI-27483 to metastatic or locally advanced pancreatic cancer patients…
- Conditions
- Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer
- Trial name
- NCT01020006
- Testing
- PCI-27483, Gemcitabine
- Where
- 17 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pharmacyclics LLC.
Pancreatic Cancer
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
The primary purpose of this study is to define the maximum tolerated dose of combination docetaxel, gemcitabine, and capecitabine in patients with pancreatic cancer. Adverse effects will be measured in study participants.
- Trial name
- NCT00320749
- Testing
- Capecitabine, Docetaxel, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tony Bekaii-Saab
Biliary Tract Cancer
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with…
- Trial name
- FOENIX-BTC (NCT07710885)
- Testing
- Futibatinib, Zimberelimab, Durvalumab
- Where
- 21 sites in Australia, Japan and 2 more
- Volunteers
- 784 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Breast Neoplasms
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC)…
- Trial name
- NCT06926868
- Testing
- Iza-bren, Nab-paclitaxel, Paclitaxel
- Where
- 295 sites in United States, Argentina and 26 more
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Cancer Resectable
Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer
Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.
- Trial name
- NCT06809374
- Testing
- gemcitabine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kochi University
Non Small Cell Lung Cancer
A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer
The purpose of this study is to compare the efficacy and safety of two different chemotherapy types in the first line treatment of advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT01005680
- Testing
- Pemetrexed, Gemcitabine, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 256 people
- Sponsor
- Eli Lilly and Company
Cholangiocarcinoma of the Bile Duct
Chemotherapy mFOLFIRINOX in Locally Advanced or Metastatic Cholangiocarcinoma
The aim of this study was to evaluate the effectiveness of modified FOLFIRINOX (mFOLFIRINOX) compared to that of gemcitabine plus oxaliplatin (Gemox) for patients with locally advanced or metastatic CCA
- Trial name
- NCT04305288
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Pancreas Adenocarcinoma
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line…
- Trial name
- NCT03377491
- Testing
- NovoTTF-200T, Gemcitabine, nab paclitaxel
- Where
- 199 sites in United States, Australia and 18 more
- Volunteers
- 571 people
- Sponsor
- NovoCure Ltd.
Pancreatic Cancer
Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer
This randomized phase II trial will compare the efficacy and toxicity of Gemcitabine plus Erlotinib versus Gemcitabine plus Erlotinib plus Oxaliplatin in patients with pancreatic cancer.
- Trial name
- NCT00564720
- Testing
- Gemcitabine, Erlotinib, Oxaliplatin
- Where
- 8 sites in Greece
- Volunteers
- 140 people
- Sponsor
- Hellenic Oncology Research Group
Intrahepatic Cholangiocarcinoma
TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma
This study is a prospective, multicenter, open, real-world clinical study. All eligible patients were assigned to experimental group (TACE combined with multi-target drugs and PD-1 inhibitors), and control group (conventional…
- Trial name
- NCT05247996
- Testing
- Transcatheter arterial chemoembolization, Multi-target Drug Therapy, Immunocheckpoint Inhibitor Therapy
- Volunteers
- 98 people
- Sponsor
- The Central Hospital of Lishui City
Metastatic Pancreatic Adenocarcinoma
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
This study is a single-arm, open-label, multi-institutional Phase I/II trial of the combination of LEE011 and everolimus in refractory mPAC.
- Trial name
- NCT02985125
- Testing
- LEE011, Everolimus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Georgetown University
Carcinoma, Small Cell
Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
The purpose of the study is to determine whether pemetrexed and gemcitabine cause good tumour shrinkage when given to patients with previously untreated extensive-stage small cell lung cancer.
- Trial name
- NCT00129974
- Testing
- pemetrexed and gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tufts Medical Center
Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma.
- Conditions
- Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma
- Trial name
- NCT03533582
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- 205 sites in United States, Australia and 4 more
- Volunteers
- 537 people
- Sponsor
- Children's Oncology Group
Non-Small Cell Lung Cancer
Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer
The combination of oxaliplatin and gemcitabine has proven activity in advanced non-small cell lung cancer (NSCLC). Due to its favorable toxicity profile, this combination is optimal for adding new agents.
- Trial name
- NCT00217282
- Testing
- oxaliplatin, gemcitabine, bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Biliary Tract Cancer, PD-1 Antibody
Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
The aim of this study is to assess the R0 resection rate of tislelizumab combined with Lenvatinib and Gemox chemotherapy in the conversion therapy of potentially resectable locally advanced BTC.
- Conditions
- Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib
- Trial name
- NCT05156788
- Testing
- PD-1+Lenvatinib+GEMOX
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreas Cancer, Non-Resectable Pancreas Carcinoma
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
The aim of the study is to compare the efficacy and toxicity of full-dose Gemcitabine and reduced-dose combination chemotherapy in patients with non-resectable pancreatic cancer, who are unfit for full-dose combination…
- Trial name
- NCT05841420
- Testing
- Gemcitabine, Nab paclitaxel
- Where
- Denmark
- Volunteers
- 98 people
- Sponsor
- Morten Ladekarl
Recurrent Pancreatic Cancer
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
To evaluate the efficacy of Tislelizumab combined with Nab-paclitaxel and Gemcitabine in the treatment of recurrent pancreatic cancer
- Trial name
- NCT04902261
- Testing
- Tislelizumab, Nab paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Changhai Hospital
Pancreatic Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with…
- Conditions
- Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer
- Trial name
- NCT01803282
- Testing
- Andecaliximab, Gemcitabine, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 236 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.